From the Journals

Cancer burden: Multiple metrics needed to clarify the big picture


 

FROM NEW ENGLAND JOURNAL OF MEDICINE

All cancers

The epidemiologic signature for all cancers combined differed somewhat by sex. Women had a rising incidence during the 1980s that was mainly driven by lung and breast cancers, according to Dr. Welch and colleagues; a continued rise since the mid-1990s was largely driven by melanoma, kidney cancer, and thyroid cancer. Declining mortality since 1990 has been primarily due to reductions in deaths from breast and colorectal cancers, and, more recently, lung cancer.

Men had a “volatile pattern” in the incidence of all cancers combined that was attributable to prostate cancer trends; drops in lung and colorectal cancer incidences were offset by rises in melanoma and kidney cancer incidences, the analysts proposed. Declining mortality since 1990 was more marked than that among women and reflects a longer period of decline in lung cancer mortality, plus reductions in deaths from prostate cancer and colorectal cancer.

“Falling mortality means that there has been real progress against cancer in the past 40 years – largely reflecting improved treatment and the decline of a uniquely powerful causal factor: cigarette smoking,” Dr. Welch and colleagues noted. “The lack of an accompanying fall in incidence is an unfortunate side effect of early cancer-detection efforts.”

Dr. Welch reported that he had no relevant disclosures. The analysis did not receive any specific funding.

SOURCE: Welch HG et al. N Engl J Med. 2019;381:1378-86. doi: 10.1056/NEJMsr1905447.

Pages

Recommended Reading

Developing Community Partnerships to Improve Breast Cancer Survivorship for Young Women
Breast Cancer ICYMI
Prognostic significance of primary tumor location in breast cancer: An Analysis of the National Cancer Database (NCDB)
Breast Cancer ICYMI
FDA issues warning for CDK 4/6 inhibitors
Breast Cancer ICYMI
Ovarian function suppression gains support for premenopausal breast cancer
Breast Cancer ICYMI
Meta-analysis supports hormone therapy-targeted therapy combo for advanced breast cancer
Breast Cancer ICYMI
Mortality after breast cancer diagnosis found higher for men
Breast Cancer ICYMI
AF risk is elevated after early-stage breast cancer diagnosis
Breast Cancer ICYMI
Physicians not yet comfortable with using social media to recruit for trials
Breast Cancer ICYMI
Gene recurrence score helps predict successful combination therapy for early breast cancer
Breast Cancer ICYMI
MONARCH 2: Abemaciclib plus fulvestrant improves overall survival
Breast Cancer ICYMI